BioStock: FDA tailwinds for BiBBInstruments

Lund-based BiBBInstruments recently reported on its first quarter for 2023. The report focuses on the US market and the recent FDA clearance for EndoDrill GI. An exciting period now awaits the company, as discussions with customers and potential distribution partners in the US are on the horizon. BioStock contacted CEO Fredrik Lindblad to find out more about his expectations for the rest of the year.

Read the interview with Fredrik Lindblad at biostock.se:

FDA tailwinds for BiBBInstruments - BioStock

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/